GE Healthcare will pay about $580m for Safeguard Scientifics-backed Clarient at $5 per common share and $20 per preferred share.
Safeguard Scientifics, a New York-listed life sciences and medical technology company, will receive $145m from the sale of its partner company Clarient to industrial conglomerate General Electric’s subsidiary.
GE Healthcare will pay about $580m for Clarient at $5 per common share and $20 per preferred share.
Safeguard floated Clarient on the Nasdaq stock exchange in 1997 but retained its partnership interest.
John Dineen, executive president of GE Healthcare, said: "Adding Clarient’s technology to our portfolio will accelerate our expansion…
